|
Comparison of the new FDA approved vaccine for prostate cancer with
hyperthermia treatment for prostate cancer!
From
Medscape Medical News
"The
availability of [sipuleucel-T] provides a new treatment option for men
with advanced prostate cancer who currently have limited effective
therapies available," said Karen Midthun, MD, acting director of the
FDA's Center for Biologics Evaluation and Research, in a press statement
In the pivotal phase 3 study, with a
median follow-up of 36.5 months, men treated with sipuleucel-T (n = 341)
had a median survival of 25.8 months, compared with men treated with
placebo (n = 171), who had a median survival of 21.7 months
Thus, with the new therapy, there was a
4.1-month median survival advantage and a 24.1% reduction in the risk
for death (hazard ratio, 0.759; P = .017), compared with placebo.
“This 4-month
extension in survival is very, very significant.” Said
David F. Penson, MD, MPH, at the AUA meeting. Dr. Penson is a professor
of medicine at the University of Southern California Los Angeles.
"These patients have a life expectancy
of about 2 years, so giving them 4 more months is pretty important. It
gives them about 20% more life. And [sipuleucel-T] does it with minimal
adverse events. So there is improved survival with good quality of
life," he added.
Us: Hyperthermia
Treatment for prostate cancer has an 87% success rate in 5 years, which
means out of 100 people that got treated with hyperthermia 87 of them
would be alive in 5 years! Sipuleuce-T has been proven to extend
prostate cancer patients’ lives for only an extra 4 months!!! Can you
see the significance in this?
According to the FDA
press release, the most common adverse reactions reported with the new
product are chills, fatigue, fever, back pain, nausea, joint ache, and
headache. The majority of adverse reactions were mild or moderate.
Serious adverse reactions, which were reported in approximately one
quarter of the patients receiving sipuleucel-T, included some acute
infusion reactions and stroke.
Us:
Hyperthermia is the proven prostate cancer treatment with minimal to
absolutely No side effects in most cases! No hair loss, nausea,
pain.. And most importantly after the treatment NO impotence,
incontinence, diarrhea for the rest of people’s life? Who wants to
live with that if you don’t have to?
In 2007, the FDA
deferred approval of
sipuleucel-T until a statistically significant improvement in survival
could be shown.
The study investigators
revealed such an improvement
at the 2009 AUA annual meeting.
We don't have anything for
patients with hormone-refractory disease.
At the time, AUA spokesman J. Brantley
Thrasher, MD, chair of the Department of Urology at the University of
Kansas Medical Center in Kansas City, said that "this will cause a big
splash."
"We don't have anything for patients
with hormone-refractory disease, which is very aggressive. . . .
Improved survival with T cell immunotherapy is really very significant,"
he said.
HYPERTHERMIA, the
Cancer Treatment with the best success rate in the world,
that allows you to
maintain your normal lifestyle while, undergoing treatment
and does not
compromise your quality of life DURING OR AFTER THE TREATMENT.
Valley Cancer
Institute has been treating and healing people for over 25 years.
It’s time the world
knew more about it…
www.vci.org
|
